Moritz B.
- Country
- Germany
- Department
- Zentrum für Kardiologie
Research Overview
- Efficacy and Safety of Durvalumab, Tremelimumab, and Enfortumab Vedotin in Perioperative Treatment of Cisplatin-Ineligible Muscle Invasive Bladder Cancer
- Phase 3 Randomized Trial of Neoadjuvant Chemotherapy with Nivolumab and BMS-986205 in Muscle-Invasive Bladder Cancer
- Evaluation of Empagliflozin Continuation Versus Placebo in Patients with Acute Decompensated Heart Failure on SGLT2 Inhibitor Therapy
Data & Insights
Has run more than one trial at 18 of 135 partner sites.
Specializations
Urological Oncology
This investigator specializes in advanced treatments for muscle-invasive bladder cancer and prostate cancer, exploring innovative therapeutic approaches for these challenging urological conditions.
- Bladder Cancer Management
- Prostate Cancer Therapeutics
- Metastatic Disease Treatment
Particular focus on neoadjuvant therapy combinations and treatment strategies for cisplatin-ineligible patients.
Novel Treatment Combinations
The investigator explores innovative therapeutic combinations including immunotherapy agents and targeted treatments for urological cancers.
- Immunotherapy Applications
- Hormone Therapy Approaches
- Radiation-based Treatments
Special interest in combining traditional and novel therapeutic approaches to improve patient outcomes.
Precision Medicine
Focus on developing personalized treatment strategies for patients with biochemically recurrent cancer and those with specific therapeutic needs.
- Biomarker-guided Therapy
- Treatment Resistance Management
- Alternative Treatment Pathways
Emphasis on tailoring treatments based on individual patient characteristics and disease markers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.